| Name | Stavudine |
| Description | Stavudine (BMY-27857), a nucleoside reverse transcriptase inhibitor analog of thymidine, has activity against HIV. |
| In vitro | In lean mice, Stavudine (500 mg/kg/day) reduces mitochondrial DNA in the liver and muscle, inducing ketoacidosis during fasting periods. In obese mice, Stavudine (500 mg/kg/day) depletes mtDNA in White Adipose Tissue (WAT). |
| In vivo | Stavudine reduces lipid content and influences the expression of lipid metabolism markers, such as C/EBPα, peroxisome proliferator-activated receptor γ, adipocyte lipid-binding protein 2, fatty acid synthase, and acetyl-CoA carboxylase. In 3T3-F442A cells, Stavudine induces apoptosis and reduces both lipid content and viability in 3T3-L1 adipocytes. Furthermore, in peripheral blood mononuclear cells (PBMC), Stavudine inhibits the production of p24 antigen by HIV-1, with an effective dose range of 0.04 μM to 0.2 μM (ED50 = 0.04 μM-0.2 μM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (223.01 mM), Sonication is recommended.
H2O : 22.4 mg/mL (99.91 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (8.92 mM), Sonication is recommended.
|
| Keywords | Stavudine | ReverseTranscriptase | Reverse Transcriptase | NucleosideAntimetabolite | Nucleoside Antimetabolite/Analog | Nucleoside Antimetabolite | nucleoside | NSC-163661 | NSC163661 | NODlikeReceptor(NLR) | NODlikeReceptor | NOD-like Receptor (NLR) | NODlike Receptor (NLR) | NOD-like Receptor | NLR | mtDNA | Inhibitor | inhibit | inflammasome | Human immunodeficiency virus | HIVProtease | HIV Protease | HIV | BMY27857 | BMY 27857 | Autophagy | Apoptosis | antiretroviral | analogue | Analog | Amyloid-β |
| Inhibitors Related | Aceglutamide | Hemin | Emtricitabine | Urea | Guanidine hydrochloride | Hydroxychloroquine | Lamivudine | Metronidazole | Formamide | Paeonol | Naringin | Alginic acid |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Bitter Compound library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
